- Home
- NIVF vs BGLC Comparison
NIVF vs BGLC Comparison
Compare NIVF & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- BGLC
- Stock Information
- Founded
- NIVF 2011
- BGLC 2017
- Country
- NIVF Thailand
- BGLC Malaysia
- Employees
- NIVF N/A
- BGLC N/A
- Industry
- NIVF
- BGLC Medical Specialities
- Sector
- NIVF
- BGLC Health Care
- Exchange
- NIVF NYSE
- BGLC Nasdaq
- Market Cap
- NIVF 12.2M
- BGLC 7.6M
- IPO Year
- NIVF N/A
- BGLC N/A
- Fundamental
- Price
- NIVF $1.16
- BGLC $0.38
- Analyst Decision
- NIVF
- BGLC
- Analyst Count
- NIVF 0
- BGLC 0
- Target Price
- NIVF N/A
- BGLC N/A
- AVG Volume (30 Days)
- NIVF 11.9M
- BGLC 116.1K
- Earning Date
- NIVF 11-16-2024
- BGLC 11-20-2024
- Dividend Yield
- NIVF N/A
- BGLC N/A
- EPS Growth
- NIVF N/A
- BGLC N/A
- EPS
- NIVF 0.21
- BGLC N/A
- Revenue
- NIVF $5,136,153.00
- BGLC $9,183,168.00
- Revenue This Year
- NIVF N/A
- BGLC N/A
- Revenue Next Year
- NIVF N/A
- BGLC N/A
- P/E Ratio
- NIVF $5.39
- BGLC N/A
- Revenue Growth
- NIVF N/A
- BGLC N/A
- 52 Week Low
- NIVF $0.55
- BGLC $0.31
- 52 Week High
- NIVF $17.24
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- NIVF 56.42
- BGLC 41.00
- Support Level
- NIVF $1.07
- BGLC $0.38
- Resistance Level
- NIVF $3.28
- BGLC $0.49
- Average True Range (ATR)
- NIVF 0.42
- BGLC 0.02
- MACD
- NIVF 0.05
- BGLC -0.00
- Stochastic Oscillator
- NIVF 22.42
- BGLC 32.66
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.